PRNewsWire
25 Aug 2026, 18:49 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Abbott received FDA authorization for the Libre Duo 10 Day, the world's first dual glucose-ketone sensing technology. — The launch of a first-of-its-kind medical device provides a significant competitive advantage and creates a new revenue stream in the diabetes care market.
+0.60Abbott is integrating the Libre Duo sensors with automated insulin delivery (AID) systems from Beta Bionics, Sequel Med Tech, Insulet, and Tandem between 2026 and 2027. — Ecosystem integration with major pump manufacturers increases device stickiness and expands the addressable market via partner channels.
+0.40Abbott is collaborating with MiniMed on an exclusive integration between dual glucose-ketone sensors and MiniMed smart dosing systems for 2027. — Exclusive partnerships with major industry players like MiniMed strengthen market positioning and create barriers to entry for competitors.
+0.30Which stocks this story touches
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
3h ago
